Navigation Links
Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004
Date:1/23/2010

considered safe. The result could be increased side effects including seizures, which in clinical trials occurred infrequently. For the same reasons, Ampyra should not be taken in combination with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same.

Q. Will taking Ampyra make it possible to stop using my walking aids?

A. There are many different types of walking aids and they address many different types of movement issues, so there is no single answer to this question. It is important that people who try the drug NOT make changes related to walking aids until they determine whether and how the drug affects them. One concern is that in the second clinical trial, a side effect experienced by some participants was increased falling. For that reason, it is important that people taking this medication continue to use caution and discuss any proposed changes in walking aids with their health care provider.

Q. What will Ampyra cost?

A. At the present time, no information has been released about how much Ampyra therapy will cost. The company expects to release that information in coming weeks.

Q. Will Ampyra be covered by my health insurance plan?

A. Coverage for Ampyra will depend on individual insurance plans. Acorda has established a team to provide support services to help patients and healthcare professionals access the drug, including working with insurance carriers and providing patient assistance programs, details of which will be available in coming weeks.

About Multiple Sclerosis

Multiple sclerosis, an unpredictable, often disabling disease of the central nervous system, interrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person ca
'/>"/>

SOURCE National Multiple Sclerosis Society
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. First Coast Oncology Deploying Both Naviscan(TM) PEM and AccuBoost(TM) Assisted Therapy to Optimize Breast Cancer Treatment
2. New Life Agency, Inc. Joins Forces With The Diamond Institute and Walgreens Specialty Pharmacy to Introduce the Nations First In Vitro Fertilization Insurance Program
3. First ShelterBoxes Arrive in Port au Prince - Pictures and Footage
4. WorldHeart Announces First U.S. Implant of Levacor(TM) VAD Implant at INTEGRIS in Oklahoma City
5. Span-America Announces First Quarter Conference Call On The Internet
6. Elbit Imaging Announces InSightecs First Non-Invasive Technology for Treatment of Uterine Fibroids Awarded MHLW Approval in Japan
7. JDRF Forms Partnership With Animas to Develop First-Generation Automated System for Managing Type 1 Diabetes
8. First Non-Invasive Technology for Treatment of Uterine Fibroids Awarded MHLW Approval in Japan
9. BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call
10. Rochester Medical Announces First Quarter 2010 Earnings Conference Call Tuesday, January 26, 2010
11. CVS Caremarks MinuteClinic Becomes First Retail Clinic Provider to Achieve Consecutive Accreditation Awards From The Joint Commission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... HILL, N.C. , Sept. 4, 2015 ... and therapeutic areas, and has become a key marketing ... still slow to fully adopt E-sampling as a supplement ... by benchmarking firm, Best Practices, LLC, physician E-sampling has ... most other large chronic areas. While E-sampling has been ...
(Date:9/4/2015)... N.J. , Sept. 4, 2015  Janssen Research ... Food and Drug Administration (FDA) has accepted for ... daratumumab as a treatment for patients with multiple ... inhibitor (PI) and an immunomodulatory agent (IMiD), or ... of therapy, including a PI and an IMiD. ...
(Date:9/4/2015)... Fair Rate Funding, a lawsuit funding firm located in ... in lawsuit filings in connection with the blood thinning drug, ... Philadelphia Court of Common Pleas has risen ... Louisiana multi---district litigation (MDL), located in the ... Louisiana , the filings are also on the rise, ...
Breaking Medicine Technology:Current and Future Trends in Physician E-Sampling Programs for the Pharmaceutical Industry 2U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 2U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 3U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 4U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 5U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 6U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 7Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 2Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 3
... March 31, 2011 Reportlinker.com announces that a ... catalogue: Molecular Diagnostics in ... http://www.reportlinker.com/p0368860/Molecular-Diagnostics-in-Infectious-Disease-Testing.html This TriMark Publications report ... diagnostics market known as molecular diagnostics testing for ...
... 2011 Reportlinker.com announces that a new ... catalogue: Gout Therapeutics Market ... as Krystexxa, Uloric, Adenuric and Colcrys to ... Gout Therapeutics Market to ...
Cached Medicine Technology:Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 2Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 3Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 4Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 5Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 6Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 7Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 8Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 9Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 10Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 11Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 12Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 13Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 14Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 15Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 16Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 17Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 18Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 2Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 3Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 4Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 5Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 6Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 7Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 8Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 9Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 10Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 11Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 12
(Date:9/4/2015)... , ... September 04, 2015 , ... ... CEREC technology is now available at CitiDent. CEREC is a newer method for ... to saving time for patients by eliminating the need for multiple appointments, CEREC ...
(Date:9/4/2015)... ... September 04, 2015 , ... Bio-Logic Aqua® Research, a fresh ... its only mission and research focus: Water Life Science®. In the current warming ... evaporation is becoming dangerously accelerated. As a result of the global fresh water, ...
(Date:9/4/2015)... Seattle, Washington (PRWEB) , ... September 04, 2015 ... ... the design and development of its first neighborhood created specifically for adults with ... located in the Phoenix Metro area and feature 30 cottage or “pocket” homes. ...
(Date:9/4/2015)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has written an open letter ... trip to the United States. , Yisrayl lays out what he says is the true ... is. Yisrayl also provides the meaning of his own name and describes what bible prophecy ...
(Date:9/3/2015)... ... September 04, 2015 , ... AlignLife of Wauwatosa is ... "There are so many children and adults who don't have the ability to buy ... "We love holding our annual Coat Drive to help those in need." , This ...
Breaking Medicine News(10 mins):Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 4Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2Health News:AlignLife is Helping to Keep the Community Warm This Winter 2
... Los Angeles Based ... ... winning video for the “ Ban Asbestos Now! ” film search which is part of a ... health implications due to exposure. Los Angeles residents Arik Cohen (writer/director), Jared Bauer (cameraman), ...
... factors have long been known to play a major role ... obesity suggests that there should be some common changes in ... change in dietary factors in the past few decades is ... However, the effect of long-term exposure to excess niacin on ...
... , This release is available in German ... after an accident or illness, a corneal transplantation could restore ... in Germany, about 7,000 await the opportunity to ... donor corneas are not common. Dr. Joachim Storsberg of the ...
... The 57 million Americans currently living with "pre-diabetes" could ... according to a new study published in this month,s ... a 6-month Weight Watchers group program, overweight or obese adults ... not only lost weight, but also significantly reduced fasting glucose ...
... received a $100,000 Grand Challenges Explorations grant from the ... an innovative global health research project led by Todd ... Mechanical Engineering, titled "Complement-based antibiotic microbeads". Sulchek,s project ... Foundation in the fourth funding round of Grand Challenges ...
... successful testing of a sensor that can instantly tell whether ... by emergency room doctors to determine whether a patient has ... diabetics do not take enough insulin. Someday the technology may ... determine whether they need more insulin. A report on the ...
Cached Medicine News:Health News:Judges Select Winner of the Ban Asbestos Now Video Search 2Health News:Judges Select Winner of the Ban Asbestos Now Video Search 3Health News:Judges Select Winner of the Ban Asbestos Now Video Search 4Health News:Synthetic eye prosthesis 2Health News:New study finds attending Weight Watchers meetings helps reduce the risk for type 2 diabetes 2Health News:Georgia Tech awarded Gates Foundation grant for innovative global health research 2
Provides access via PDA to determine whether imaging examinations are necessary based on symptons and which studies will generate the most information....
Provides quick access to information needed to make diagnoses and treatment decisions....
PDA formatted guide containing outlines and detailed information on the diagnosis and treatment of HIV infection and AIDS....
PDA application providing a complete guide for the diagnosis and management of electrolyte disorders....
Medicine Products: